Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Postmarketing Periodic Reports Should Be Biannual, Not Quarterly - Ligand

Executive Summary

Postmarketing periodic adverse event reports should be required every six months following product approval instead of every three months, Ligand suggested in recent comments on FDA's draft guidance "Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines."

You may also be interested in...



FDA Plans Proposed Rule To Amend Expedited Safety Reporting Regulations

FDA is planning to propose additional amendments to its expedited safety reporting regulations based on guidelines issued by the International Conference on Harmonization.

FDA Proposed Rule Will Require MedDRA for Postmarketing AE Reporting

FDA's Suspected Adverse Drug Reaction proposed rule will seek to require the use of MedDRA terminology in submissions of postmarketing adverse event reports, the agency told a Drug Information Association workshop on MedDRA implementation Oct. 30 in Washington, D.C.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS038002

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel